Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Br J Pharmacol. 2011 Jun;163(3):484-95. doi: 10.1111/j.1476-5381.2011.01256.x.

T-type voltage-gated calcium channels as targets for the development of novel pain therapies.

Author information

  • 1Department of Anesthesiology and Neuroscience, University of Virginia School of Medicine, Charlottesville, 22908-0710, USA. st9d@virginia.edu

Abstract

It is well recognized that voltage-gated calcium (Ca(2+)) channels modulate the function of peripheral and central pain pathways by influencing fast synaptic transmission and neuronal excitability. In the past, attention focused on the modulation of different subtypes of high-voltage-activated-type Ca(2+) channels; more recently, the function of low-voltage-activated or transient (T)-type Ca(2+) channels (T-channels) in nociception has been well documented. Currently, available pain therapies remain insufficient for certain forms of pain associated with chronic disorders (e.g. neuropathic pain) and often have serious side effects. Hence, the identification of selective and potent inhibitors and modulators of neuronal T-channels may help greatly in the development of safer, more effective pain therapies. Here, we summarize the available information implicating peripheral and central T-channels in nociception. We also discuss possible future developments aimed at selective modulation of function of these channels, which are highly expressed in nociceptors.

© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

PMID:
21306582
[PubMed - indexed for MEDLINE]
PMCID:
PMC3101611
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Blackwell Publishing Icon for PubMed Central
    Loading ...
    Write to the Help Desk